Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent docetaxel + prednisone in hormone-refractory prostate cancer
2006-005364-65Phase 2Completed
- Sponsor
- AU Optronics
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and prednisone in castration-resistant prostate cancer (CRPC), sponsored by AU Optronics. Primary endpoints: PSA and/or measurable response to initial treatment and re-treatment after each treatment holiday and Major toxic events (percentage of patients with > Grade 2 toxicity). Started Apr 2007; status: completed.
02
Drugs
docetaxelprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2006-005364-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005364-65.